{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:40:04Z","timestamp":1792651204098,"version":"4.5.0"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T00:00:00Z","timestamp":1543449600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2018.00562","type":"journal-article","created":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T05:33:03Z","timestamp":1543469583000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Spontaneous Regression of Ovarian Carcinoma After Septic Peritonitis; A Unique Case Report"],"prefix":"10.3389","volume":"8","author":[{"given":"Thijs","family":"Roelofsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Wefers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A. J.","family":"Gorris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes C.","family":"Textor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leon F. A. G.","family":"Massuger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I. Jolanda M.","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne M.","family":"van Altena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,11,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.ygyno.2010.01.019","article-title":"Ovarian cancer creates a suppressive microenvironment to escape immune elimination","volume":"117","author":"Yigit","year":"2010","journal-title":"Gynecol Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.ygyno.2016.05.007","article-title":"Ovarian cancer and the immune system - The role of targeted therapies","volume":"142","author":"Turner","year":"2016","journal-title":"Gynecol Oncol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.4103\/0976-9668.82318","article-title":"Immunity over inability: the spontaneous regression of cancer","volume":"2","author":"Jessy","year":"2011","journal-title":"J Nat Sci Biol Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"246","DOI":"10.4103\/0019-509X.82887","article-title":"The role of innate immunity in spontaneous regression of cancer","volume":"48","author":"Thomas","year":"2011","journal-title":"Indian J Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s41581-018-0005-7","article-title":"Mechanisms and treatment of organ failure in sepsis","volume":"14","author":"Lelubre","year":"2018","journal-title":"Nat Rev Nephrol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/nri.2017.36","article-title":"The immunopathology of sepsis and potential therapeutic targets","volume":"17","author":"van der Poll","year":"2017","journal-title":"Nat Rev Immunol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/nri3552","article-title":"Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy","volume":"13","author":"Hotchkiss","year":"2013","journal-title":"Nat Rev Immunol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"347","DOI":"10.4049\/jimmunol.1701262","article-title":"Eight-color multiplex immunohistochemistry for simultaneous detection of multiple immune checkpoint molecules within the tumor microenvironment","volume":"200","author":"Gorris","year":"2018","journal-title":"J Immunol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.ygyno.2015.02.019","article-title":"Cellular immunotherapy in ovarian cancer: targeting the stem of recurrence","volume":"137","author":"Wefers","year":"2015","journal-title":"Gynecol Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S1471-4906(02)02302-5","article-title":"Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes","volume":"23","author":"Mantovani","year":"2002","journal-title":"Trends Immunol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/j.semcancer.2008.03.004","article-title":"Macrophage polarization in tumour progression","volume":"18","author":"Sica","year":"2008","journal-title":"Semin Cancer Biol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/nm1093","article-title":"Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival","volume":"10","author":"Curiel","year":"2004","journal-title":"Nat Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1126\/science.3489291","article-title":"A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes","volume":"233","author":"Rosenberg","year":"1986","journal-title":"Science"},{"key":"B14","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1126\/science.1129003","article-title":"Cancer regression in patients after transfer of genetically engineered lymphocytes","volume":"314","author":"Morgan","year":"2006","journal-title":"Science"},{"key":"B15","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/nrc2355","article-title":"Adoptive cell transfer: a clinical path to effective cancer immunotherapy","volume":"8","author":"Rosenberg","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.imbio.2006.05.021","article-title":"Targeting antigens to dendritic cells in vivo","volume":"211","author":"Tacken","year":"2006","journal-title":"Immunobiology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"eaao5931","DOI":"10.1126\/scitranslmed.aao5931","article-title":"Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer","volume":"10","author":"Tanyi","year":"2018","journal-title":"Sci Transl Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"4801","DOI":"10.1158\/1078-0432.CCR-13-1185","article-title":"A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside","volume":"19","author":"Chiang","year":"2013","journal-title":"Clin Cancer Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"5511","DOI":"10.1200\/JCO.2016.34.15_suppl.5511","article-title":"Anti-mesothelin chimeric antigen receptor T cells in patients with epithelial ovarian cancer","volume":"34","author":"Tanyi","year":"2016","journal-title":"J Clin Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1080\/21645515.2015.1075106","article-title":"Tumor infiltrating lymphocyte therapy for ovarian cancer and renal cell carcinoma","volume":"11","author":"Andersen","year":"2015","journal-title":"Hum Vacc Immunother."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/2162402X.2018.1502905","article-title":"Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study","volume":"1","author":"Pedersen","year":"2018","journal-title":"OncoImmunology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"5513","DOI":"10.1200\/JCO.2017.35.15_suppl.5513","article-title":"Pembrolizumab in patients (pts) with PD-L1\u2013positive (PD-L1+) advanced ovarian cancer: Updated analysis of KEYNOTE-028","volume":"35","author":"Varga","year":"2017","journal-title":"J Clin Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1158\/1078-0432.CCR-17-1805","article-title":"Exceptional response to pembrolizumab in a metastatic, chemotherapy\/radiation-resistant ovarian cancer patient harboring a PD-L1-genetic rearrangement","volume":"24","author":"Bellone","year":"2018","journal-title":"Clin Cancer Res."},{"key":"B24","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","article-title":"Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer","volume":"33","author":"Hamanishi","year":"2015","journal-title":"J Clin Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1016\/S1470-2045(18)30673-9","article-title":"Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study","volume":"19","author":"Barlesi","year":"2018","journal-title":"Lancet Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1002\/cncr.31293","article-title":"Safety profile of avelumab in patients with advanced solid tumors: a pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials","volume":"124","author":"Kelly","year":"2018","journal-title":"Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"5533","DOI":"10.1200\/JCO.2016.34.15_suppl.5533","article-title":"Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent\/refractory ovarian cancer from the JAVELIN Solid Tumor phase Ib trial: Safety and clinical activity","volume":"34","author":"Disis","year":"2016","journal-title":"J Clin Oncol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"45","DOI":"10.4161\/viru.26516","article-title":"The changing immune system in sepsis: is individualized immuno-modulatory therapy the answer?","volume":"5","author":"Boomer","year":"2014","journal-title":"Virulence"},{"key":"B29","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1615\/CritRevImmunol.v28.i2.10","article-title":"Pathogen-associated molecular pattern in cancer immunotherapy","volume":"28","author":"Hobohm","year":"2008","journal-title":"Crit Rev Immunol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1159\/000049008","article-title":"Fever, cancer incidence and spontaneous remissions","volume":"9","author":"Kleef","year":"2001","journal-title":"Neuroimmunomodulation"},{"key":"B31","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s00262-014-1637-5","article-title":"Fever and the use of paracetamol during IL-2-based immunotherapy in metastatic melanoma","volume":"64","author":"Kostner","year":"2015","journal-title":"Cancer Immunol Immunother."},{"key":"B32","doi-asserted-by":"publisher","first-page":"614","DOI":"10.3389\/fimmu.2014.00614","article-title":"Molecular mechanisms that influence the macrophage M1\u2013M2 polarization balance","volume":"5","author":"Wang","year":"2014","journal-title":"Front Immunol."},{"key":"B33","first-page":"1035","article-title":"Toll-like receptor 4 (TLR4) promotes survival of ovarian cancer cells through induction of cell proliferation and apoptosis resistance","volume":"68","author":"Szajnik","year":"2008","journal-title":"Cancer Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"4353","DOI":"10.1038\/onc.2009.289","article-title":"TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer","volume":"28","author":"Szajnik","year":"2009","journal-title":"Oncogene"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1164\/rccm.201301-0036CP","article-title":"Immunotherapy for the adjunctive treatment of sepsis: from immunosuppression to immunostimulation. time for a paradigm change?","volume":"187","author":"Leentjens","year":"2013","journal-title":"Am J Respir Crit Care Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMra021333","article-title":"The pathophysiology and treatment of sepsis","volume":"348","author":"Hotchkiss","year":"2003","journal-title":"N Engl J Med."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2018.00562\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T05:33:05Z","timestamp":1543469585000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2018.00562\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,29]]},"references-count":36,"alternative-id":["10.3389\/fonc.2018.00562"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2018.00562","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,29]]},"article-number":"562"}}